| 2026-05-13 | Presentation | Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level |
| 2025-12-02 | Presentation | Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks |
| 2025-11-25 | Presentation | Explorations Towards the Selection of a Potential Best-in-Class HBV ASO |
| 2025-11-12 | Presentation | 2021 |
| 2025-11-12 | Presentation | Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV |
| 2025-10-15 | Presentation | Lead Optimization and Selection of a Potential Best-in-Class HBV ASO |
| 2025-09-20 | Presentation | The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments |
| 2025-09-20 | Presentation | Antisense oligonucleotide-based strategy to target hepatitis delta virus infections |
| 2025-08-29 | Presentation | A Syrian hamster model of persistent HDV infection |
| 2025-04-23 | Presentation | ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice |
| 2025-03-18 | Presentation | ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study |
| 2024-11-15 | Presentation | ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2 |
| 2024-11-08 | Presentation | Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection |
| 2024-10-01 | Presentation | Discovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis |
| 2024-06-08 | Presentation | Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs |
| 2024-06-08 | Presentation | Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles |
| 2024-06-04 | Presentation | Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends |
| 2024-03-28 | Presentation | ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB |
| 2023-12-05 | Presentation | Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg |
| 2023-11-13 | Presentation | Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
| 2023-07-05 | Presentation | Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma |
| 2023-07-05 | Presentation | siRNA ALG-125755, Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B |
| 2023-05-15 | Presentation | Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor |
| 2023-05-08 | Presentation | Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) |
| 2023-02-15 | Presentation | ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection |
| 2023-02-15 | Presentation | The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT |
| 2023-02-15 | Presentation | ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB) |
| 2023-02-10 | Presentation | Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV |
| 2022-12-07 | Presentation | Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19 |
| 2022-11-21 | Presentation | Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model |
| 2022-11-03 | Presentation | Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers |
| 2022-11-03 | Presentation | Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB) |
| 2022-10-20 | Presentation | Oral 3CL-Protease Inhibitors for Treating Coronaviral Infections |
| 2022-10-20 | Presentation | Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model |
| 2022-03-24 | Presentation | Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development |
| 2022-03-04 | Presentation | Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG-125755 in HBV Infected Cells and the AAV HBV Mouse Model |
| 2021-10-22 | Presentation | Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB) |
| 2021-10-13 | Presentation | Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model |
| 2021-02-22 | Presentation | The 3CLpro™ Inhibitor ALG-097111 Potently Inhibits SARS-CoV-2 Replication in Hamsters |
| 2020-11-22 | Presentation | Structure-based discovery of potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitors using a multiplex screening platform |